

#### LEADERSHIP TEAM

Stephen Van Deventer  
**Chairman & CEO**

Kimberly Van Deventer  
**President & Director**

Brian Harris  
**VP Corporate Development & Director**

Greg Reid  
**Director**

Matt Coltura  
**Director**

Shabira Rajan, MBA, CPA, CGA  
**Chief Financial Officer & Controller**

Mak Jawadekar, PhD  
**Chief Science Officer**

Harry Parekh, PhD, BSc Honst  
**Chief Research Officer**

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

#### Our Vision

Our Vision is to be a leader in the preventive health sciences bringing innovative options for preventive and curative therapies utilising organic and nature identical products.

#### Keys to Success

Management with extensive research experience, product development experience, deep corporate strategy and capital markets leadership. Partnering with leading industry experts and companies.

#### Highlights:

- Pursuing dual-gene therapy research as both a preventative measure and possible treatment for diabetes and obesity.
- Developing sol-gel, nose-to-brain delivery system, for superior time released delivery of cannabinoid-based medications.
- Advancing its proprietary research on blue scorpion venom as a potential treatment for cancer tumors and metastatic lesions.
- Signed LOI for a Research and Development Program engineering peptide therapeutics for non-addictive analgesics.

## UNIQUEST

*Biopharma Research & Development Partner*

Partnered Research and Development programs with UniQuest, the main commercialisation company for the University of Queensland. Under the agreements, intellectual property arising from the carrying out of, results developed during, or created by the programs will be owned by PreveCeutical.



#### PEPTIDE RESEARCH PROGRAM

- Identification of peptides
- Synthesis and stabilization




#### SOL-GEL DELIVERY PLATFORM

- Analysis of plant-derived CBDs
- Formulation of CBD infused soluble-gels
- Perform delivery studies



#### DUAL GENE THERAPY

- Tissue targeted, bio-responsive gene delivery systems
- Systematic evaluation towards gene and protein silencing in appropriate models – *multiple phases Curative therapy for diabetes & obesity*



## RESEARCH AND DEVELOPMENT PROGRAMS

### Dual Gene Therapy

*Lead by: Dr. Harendra Parekh, PreveCeutical Chief Research Officer & UQ researcher*

This program paves the way for preclinical evaluation of proprietary chemistry toward the gene target implicated in both diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.

- Four year research program, starting September 2017
- Demonstrated proof of concept, over five years of multi-disciplinary research



### Sol-Gel Delivery Platform

*Lead by: Dr. Harendra Parekh, PreveCeutical Chief Research Officer & UQ researcher*

Developing what we believe to be the first FDA approved, CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Sol-gels are taken via nasal (systemic) administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery.

*Key advantages of our proprietary formulations:*

- Eliminates first pass metabolism (stomach, intestines, liver) – potentially improving bioavailability
- Extended time release, up to seven days – potentially alleviating side effects of high dosage therapeutics and reducing symptoms
- *Universally-patient friendly*, children and adults
- Expected market deployment with licensed medical marijuana company partners is 18 months



### Venom Re-engineering (Peptide Research Program)

*Designed and directed by: Dr. Mak Jawadekar, PreveCeutical Chief Science Officer*

PreveCeutical, and partner Uniquet, currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours.

*Our initial focus:*

- Targeting aggressive form of brain cancer (glioma)
- Screen our library of nature identical peptides across a range of other cancer



### Engineering Peptide Therapeutics for Non-Addictive Analgesia

*Lead by: Dr. Harendra Parekh, PreveCeutical Chief Research Officer & UQ researcher*

PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a letter of intent proposing to expand the use of their disulfide linker technology to develop non-addictive analgesics for moderate-to-severe pain.

*Involves:*

- Peptide library synthesis
- Pharmacological evaluation
- Pharmacokinetic assessment and efficacy determinations



### Joint Venture

Joint Venture with Sports 1 Marketing to develop a therapy geared towards athletes who suffer from concussions (Mild Traumatic Brain Injury).

### Next Steps

International Licensing Agreements/Further Research and Development Projects/Growth Potential

#### DISCLAIMER

This fact sheet ("Fact Sheet") has been prepared by PreveCeutical Medical Inc. ("PreveCeutical" or the "Company") (CSE: PREV) (FSE: 18H). This Fact Sheet contains certain forward-looking statements relating to the potential business, financial performance and results of the Company and/or industries and markets in which it is or may operate within, including forward-looking forecasts. These statements may contain words such as "will", "expects", "anticipates", "believes", "estimates" and words of similar import. Any forward-looking statements and other information contained in this Fact Sheet, including assumptions, opinions, forecasts and views, including those cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. As such by the nature of any forward-looking statement, relying on such statements involves risk. This Fact Sheet may contain information which has been sourced from third parties believed to be reliable, but without independent verification by the Company, its board of directors, management, employees, consultants, agents, or affiliates. This Fact Sheet is prepared for discussion and informational purposes only, and does not constitute, and should not be construed as, any general advertisement, general solicitation, offer, invitation, solicitation, or recommendation to buy or sell any of the securities issued by the Company in any jurisdiction, and does and will not constitute or form or be part of any offering material. Such an offer can only be made by prospectus, registration statement, other authorized offering document, or in reliance on an exemption to such requirement(s). This Fact Sheet is not meant for and should not be distributed to U.S. Persons (as defined in Regulation S of the United States Securities Act of 1933, as amended) or otherwise distributed in the United States of America. This Fact Sheet has not been reviewed or registered with any public authority, securities commission, stock exchange, or regulated market place. You (the reader) are solely responsible for your own assessment of the information contained in this Fact Sheet. This Fact Sheet may be subject to corrections and change at any time without notice. Neither the Company nor any subsidiary of the Company or any such person's board of directors, management, employees, consultants, agents, or affiliates intends to, and neither the delivery of this Fact Sheet nor any further discussions with any recipient shall, under any circumstances, create any implication that the Company or any of the aforementioned parties assumes any obligation to update or correct the information herein unless required by applicable law. The information in this Fact Sheet is current as of the date of this Fact Sheet noted on its first page or the date of publication (as applicable), and readers are encouraged to review the Company's public filings on its SEDAR profile on [www.sedar.com](http://www.sedar.com).

#### CONTACT

**Stephen Van Deventer**

Chairman & CEO

Cell: 1 (604) 306-9669

Office: 1 (604) 416-777 7 ext.6230

[steve@preveceutical.com](mailto:steve@preveceutical.com)

**Deanna Kress**

Director of Corporate

Communications & Investor Relations

Cell: 1(778) 999-6063

Office: 1(604) 416-7777 ext.6288

[deanna@preveceutical.com](mailto:deanna@preveceutical.com)